JUL 24, 2019 9:55 AM PDT

Understanding The Anti-Malarial Drug Primaquine (PQ)

WRITTEN BY: Nouran Amin

Scientists at the Liverpool School of Tropical Medicine (LSTM) have advanced their experiments to understand the mode of action for the anti-malarial drug primaquine (PQ)—which is currently lethal for patients with a glucose-6-phoshate dehydrogenase (G6PD) deficiency. The anti-malarial drug primaquine (PQ) studies can eventually lead to safer and effective therapeutics for Malaria.

"The antimalarial primaquine is a cornerstone of global efforts to eliminate malaria, for some 70 years it has been the only drug registered that has been demonstrated to be able to cure relapsing malaria and block transmission of the disease,” says LSTM's Professor Giancarlo Biagini. “However, little has previously been understood about the drug's mode of action, which is seriously undermining efforts to improve the safety and pharmacology profile of this important drug class”

Experiments were designed to replicate the interaction between drug and the host enzymes that catalyze the production of cytotoxic materials from the metabolites of PQ. Findings from these experiments were published in the journal Nature Communications and shows how PQ displays selectivity towards specific parasitic stages after a Malaria infection.

London School of Tropical Medicine: Plasmodium falciparum late-stage gametocyte, one of the parasite stages targeted by primaquine. Credit: LSTMED.AC.UK

The hunt for malaria therapeutics is critical for treating millions of affected people in malaria-endemic countries and for eradicating global malaria.

Learn more about the 2016 report by the World Health Organization (WHO) addressing global malaria challenges:

"This is why an understanding of how the drug works is central to replicating its most significant elements,” stated Professor Biagini. "This work has been possible with CDD given the multidisciplinary nature of the team. The current study makes a significant advancement in our understanding of PQ mechanism of action. This new knowledge is key to the development of newer and safer, broad-spectrum antimalarial drugs, work currently underway within our group."

Source: London School of Tropical Medicine

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 21, 2020
Microbiology
A Fast, Cheap Way to See if Two Antibiotics Work Together
SEP 21, 2020
A Fast, Cheap Way to See if Two Antibiotics Work Together
When a person has a bacterial infection, doctors can prescribe antibiotics. Some antibiotics combos can work better than ...
SEP 20, 2020
Drug Discovery & Development
New Drug Shows Promise in Treating Advanced COVID-19
SEP 20, 2020
New Drug Shows Promise in Treating Advanced COVID-19
As the COVID-19 pandemic rages on, the search for drugs to combat the virus is ongoing. Now, scientists have found that ...
OCT 13, 2020
Immunology
Early Tips For Cell & Gene Therapy Regulatory Compliance
OCT 13, 2020
Early Tips For Cell & Gene Therapy Regulatory Compliance
Cell and gene therapies hold great promise for improved health outcomes. Now is the time to advance life-saving research ...
OCT 15, 2020
Cannabis Sciences
Can Cannabis Treat Traumatic Brain Injury?
OCT 15, 2020
Can Cannabis Treat Traumatic Brain Injury?
Traumatic brain injury (TBI) happens when the head is violently hit by an object or when an object pierces the skull and ...
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
NOV 22, 2020
Cannabis Sciences
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
NOV 22, 2020
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
Researchers from St. Michael’s Hospital in Toronto have found that two synthetic cannabinoids available on prescri ...
Loading Comments...